Tectonic Therapeutic, Inc. disclosed a material event
SEC 8-KRead source ↗
Tectonic Therapeutic, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 2 selling3 purchases and 11 sales by directors and officers, last 12 monthsInsider trades
- Funds64 adding, 51 cuttingOf 25 active managers that changed their stake, 15 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 13% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Tectonic Therapeutic, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 73% and a beta of 0.8 against the S&P 500.
- Heavily shorted. 23.0% of the shares available to trade are sold short (9.1 days of average volume to cover).
Latest results
- Earnings per share
- -$1.18 against an average estimate of -$1.35: beat by 12.9%
- Share reaction
- +4.8% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
- Next report
- November 5, 2026; average EPS estimate -$1.21
Price chart
- 1 day-4.0%
- 1 week-4.9%
- 1 month-15.8%
- This year-9.0%
- 1 year+4.0%
- 5 years-73.9%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 6, 2026
- Next results (est.)
- November 5, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Announcement
- Results
Tectonic Therapeutic, Inc. reported results
SEC 8-KRead source ↗
No model value for Tectonic Therapeutic, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Tectonic Therapeutic, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Tectonic Therapeutic, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.21 (range −$1.21 to −$1.21) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$5.77 | — | — | 0% |
| Next | −$4.76 | +18% | — | 0% |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.35 | −$1.18 | +12.9% |
| Mar 2026 | −$1.17 | −$1.34 | −14.9% |
| Dec 2025 | −$1.11 | −$1.03 | +7.6% |
| Sept 2025 | −$1.05 | −$1.02 | +2.6% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 23.0% of tradable shares
- Days to cover
- 9.07 at average volume
- Short interest, 1 month
- +0% to October 15, 2026
- Held by institutions
- 69% of shares
- Held by insiders
- 37.7% of shares
- Employees
- 60 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| TECX | −72% | −82% | +92% | +183% | −55% | −9% |
| Industry peers (median) | −35% | −56% | −18% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| TECX | 33% | 33% | 58% | 58% | 58% | 46% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| TECX | −82% | −86% | −68% | −92% | −73% | −50% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since June 21, 2018: 100% from September 26, 2018 to June 21, 2024. Getting back needed a 45071% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $16.44 – $37.93
- From 52-week high
- −50.0%
- vs 50-day average
- −26.0%
- vs 200-day average
- −32.4%
- Volatility (1 year)
- 73%
- Beta vs S&P 500
- 0.84
Share price after results
- Next day
- 5 up, 7 down typical move ±13.2%
- After a week
- 8 up, 4 down typical move ±10.8%
- After a month
- 8 up, 4 down typical move ±21.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +4.8% | +0.5% | +15.0% | +4.0% |
| May 7, 2026 | −0.1% | +0.5% | +2.7% | +0.3% |
| February 26, 2026 | +1.5% | −1.0% | +20.5% | +27.0% |
| November 6, 2025 | +17.5% | −1.0% | +6.9% | +21.7% |
| August 7, 2025 | −3.7% | +0.7% | +5.7% | −29.6% |
| May 8, 2025 | +4.2% | +0.6% | +9.1% | +29.0% |
| March 20, 2025 | −3.5% | −0.3% | −13.7% | −18.2% |
| November 7, 2024 | −2.0% | +1.2% | −3.5% | +10.6% |
| August 14, 2024 | +4.2% | +2.0% | +0.2% | +10.9% |
| June 20, 2024 | −91.8% | −0.4% | −3.2% | −2.3% |
| May 11, 2023 | −4.5% | −0.3% | +25.4% | +74.6% |
| March 23, 2023 | −20.3% | +0.9% | −23.6% | −26.8% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $480M
- Institutions reporting
- 123
- Shares held vs prior quarter
- ▲ 1.1%
- Positions opened / closed
- 25 / 11
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $97.3M | 2.8M | 20.3% | ▲ 0.5% |
| Tcg Crossover Management, LLC | $41.4M | 1.2M | 8.6% | 0.0% |
| Aberdeen Group PLC | $39.3M | 1.1M | 8.2% | 0.0% |
| Blackrock, Inc. | $29.7M | 863K | 6.2% | ▲ 0.3% |
| First Light Asset Management, LLC | $27.5M | 801K | 5.7% | ▲ 23.6% |
| Baker Bros. Advisors LP | $20.9M | 608K | 4.4% | 0.0% |
| 5Am Venture Management, LLC | $20.9M | 607K | 4.3% | 0.0% |
| Braidwell LP | $20.5M | 597K | 4.3% | ▼ 29.5% |
| Vanguard Capital Management LLC | $16.8M | 489K | 3.5% | ▲ 3.2% |
| Vestal Point Capital, LP | $14.6M | 425K | 3.0% | ▲ 29.6% |
| Bollard Group LLC | $10.4M | 303K | 2.2% | 0.0% |
| Kennedy Capital Management LLC | $9.7M | 282K | 2.0% | ▼ 1.6% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Tectonic Therapeutic, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $235,160 3 trades by 2 insiders, last 12 months Insider sales History → $651,007 11 trades by 2 insiders · 100% under pre-set plans
Net ▼ $415,847 net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Mcnamara Peter Chief Scientific Officer | September 30, 2026 | Sell pre-set plan | 536 | $23.04 | $12,349 |
| Mcnamara Peter Chief Scientific Officer | August 25, 2026 | Sell pre-set plan | 43 | $36.52 | $1,570 |
| Mcnamara Peter Chief Scientific Officer | August 12, 2026 | Sell pre-set plan | 43 | $35.00 | $1,505 |
| Mcnamara Peter Chief Scientific Officer | June 30, 2026 | Sell pre-set plan | 172 | $35.00 | $6,020 |
| Ruddy Marcella K. Chief Medical Officer | May 4, 2026 | Sell pre-set plan | 1,065 | $30.00 | $31,950 |
| Ruddy Marcella K. Chief Medical Officer | April 1, 2026 | Sell pre-set plan | 1,000 | $31.05 | $31,050 |
| Mcnamara Peter Chief Scientific Officer | March 6, 2026 | Sell pre-set plan | 6,047 | $30.00 | $181,410 |
| Mcnamara Peter Chief Scientific Officer | March 6, 2026 | Sell pre-set plan | 215 | $35.00 | $7,525 |
| Ruddy Marcella K. Chief Medical Officer | March 6, 2026 | Sell pre-set plan | 10,000 | $30.00 | $300,000 |
| Mcnamara Peter Chief Scientific Officer | March 4, 2026 | Sell pre-set plan | 1,650 | $25.00 | $41,250 |
| Mcnamara Peter Chief Scientific Officer | March 3, 2026 | Sell pre-set plan | 1,649 | $22.06 | $36,377 |
| Reicin Alise Chief Executive Officer | February 11, 2026 | Buy | 2,500 | $21.10 | $52,750 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced
- August 6, 2026
- May 7, 2026
- February 26, 2026
- November 6, 2025
- August 7, 2025
- May 8, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Tectonic Therapeutic, Inc. in brief
- What does Tectonic Therapeutic, Inc. do?
- Tectonic Therapeutic, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Tectonic Therapeutic, Inc.'s stock ticker?
- Tectonic Therapeutic, Inc. trades under the ticker TECX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Tectonic Therapeutic, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Tcg Crossover Management, LLC and Aberdeen Group PLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Tectonic Therapeutic, Inc. stock?
- Over the last 12 months, Tectonic Therapeutic, Inc.'s directors and officers reported 3 open-market purchases and 11 sales on Form 4. The insider trading page charts every trade.
- When is Tectonic Therapeutic, Inc.'s next earnings date?
- Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Tectonic Therapeutic, Inc. announces its own schedule.
Follow research on Tectonic Therapeutic, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.